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Abstract
Background: As biobank research has become increasingly widespread within biomedical research, study-specific
consent to each study, a model derived from research involving traditional interventions on human subjects, has
for the sake of feasibility gradually given way to alternative consent models which do not require consent for every
new study. Besides broad consent these models include tiered, dynamic, and meta-consent. However, critics have
pointed out that it is normally not known at the time of enrolment in what ways samples deposited in a biobank
may be used in future research and that, for a consent to be informed, exactly this kind of knowledge is required.
Therefore, there is an ongoing debate about the ethical acceptability of going for less than study-specific consent.
Main text: In light of this debate we address the question of how to best protect participants against relevant risks
and violations of autonomy. We apply the central aims of the informed consent process to the unique
circumstances of biobank research where samples and data in many cases are stored for long periods of time and
reused in subsequent studies. Thereby we are able to formulate a set of criteria focusing both on the risk of
informational harm and the potential violation of participants’ values. We compare existing models of consent
based on their ability to satisfy the criteria, and we find that the broad consent model offers the best level of
protection for participants, although, it suffers from a few important deficiencies with regards to protection against
participant value violations and long-term protection of autonomy, if it is applied without qualifications. For this
reason, we propose modifications to the current broad consent model, in order to ensure that it provides
protection of autonomy and participant values through strong ethical review and continuous communication.
Conclusion: We conclude that a modified form of broad consent is ethically superior in biobank research, not only
because it is most feasible but primarily because it offers the best available protection against the hazards facing
research subjects in this form of research.
Keywords: Informed consent, Biobank research, Autonomy, Consent models, Risks, Ethics
Background
The emergence of biobanks as a vital research tool in
the medical sciences has led to widespread debate in the
literature about how to best handle the informed con-
sent procedures governing the enrolment of participants
in research, and the subsequent use of participant sam-
ples and data in other studies (see e.g. [1–9].
Before the ethical debate about biobanks emerged in
the 1990s [10], study-specific informed consent (wherein
consent is obtained from all participants immediately
before each new study is undertaken, and the consent
only covers the specific study in question) was the norm
in human subject research, and it became the foundation
of international as well as national research ethics pol-
icies [11–13]. This consent was designed to ensure that
participants were well informed about the goals of the
research and about any relevant risks or benefits of
participation. However, the practicalities of biobank re-
search (in particular the size of the cohorts and the fre-
quency of new studies) have made it difficult to replicate
study-specific consent in biobanks. This has led to the
development of new and adapted consent procedures
that aim to overcome these difficulties while retaining
the protection of participants that informed consent
offers (see e.g. [7, 8]).
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To date, different versions of the broad consent model
have generally been adopted by those managing bio-
banks (although there are significant variations in the
implementation of informed consent across countries,
based on both culture and legislation). When this model
is applied, general consent is gathered at the time of en-
rolment (subject to a set of limitations and restrictions
that are formulated by the biobank and/or a regulatory
authority and stated in the consent form). Subsequently,
samples stored in the biobank can be used for new stud-
ies that fall within the scope of the consent without re-
obtaining consent from participants. Proponents defend
the broad model by arguing that it is the best way to
make large-scale biobank research feasible. However,
critics have pointed out that it is normally not known at
the time of enrolment in what ways samples deposited
in a biobank may be used in future research and added
that it seems that, for a consent to be informed, exactly
this kind of knowledge is required [6].
In this way, arguments often revolve around how differ-
ent models of consent measure up against one another
and the extent to which each succeeds in offering the
same level of protection as the traditional forms of con-
sent known from clinical research. In this paper, we sug-
gest that this type of comparison is of limited use. We
argue that study-specific consent has rightly fallen out of
favor in biobank research precisely because the context
and structure of the latter differs significantly from that
seen in the studies for which study-specific consent was
originally designed. We conclude that the traditional con-
sent model does not offer a useful basis of comparison,
and hence does not allow us to gauge the quality of in-
formed consent models in the biobank context.
Study-specific consent procedures are effective in
informing potential participants about the particular, often
physical, risks posed by a specific study. Plainly, these are
the most important risks to consider in traditional human-
subject clinical research. However, after the procurement
of the initial sample and its allocation to the biobank,
physical risks to participants are minimal. On the other
hand, the risk of informational harm from leaks or hacks,
or violations of a participant’s values as a consequence of
the types or methods of research carried out in the bio-
bank, are correspondingly larger. The likelihood of these
harms, moreover, is dependent on the governance and
policies of the biobank, rather than the way in which any
given research project is conducted. The purpose of in-
formed consent (which will be explored in more detail
below) is to inform participants about the relevant risks
and benefits of participation and the goals of the research,
and to allow participants to exercise their autonomy.
Study-specific consent was designed to inform participants
about study-specific risks of research projects, because his-
torically these were the clearest risks of participation in
traditional research projects. However, the risks associated
with biobank research are quite different and more gen-
eral, and for this reason it cannot simply be assumed that
the study-specific consent model will provide suitable pro-
tection for participants in biobanks. We argue that because
the risk profile has changed, a different model of consent
structured to address the relevant risks is needed for
biobank-related research.
In this paper we argue that a modified version of
broad consent best serves to protect participants in bio-
bank research, based on the novel criteria-based model
of assessment of consent models presented in this paper.
We begin, in the next section, by providing a general
overview of the main models of informed consent and
the principal criticisms that have been levelled at them.
We then turn to the aims of the informed consent
process and discuss how these aims apply to biobank re-
search. Drawing on this discussion, we formulate a set of
criteria designed to ensure that the aims of the informed
consent process are met in the context of biobanks. This
allows us to evaluate models of consent that have been
presented in the literature by this novel standard. We
conclude that, as long as it is combined with strong in-
stitutional protections and provides long-term protec-
tion for participants, the broad consent model is best
suited to meet the stated aims of informed consent in
biobank research. In other words, the broad consent
model is best, provided it is also deep.
Proposed models of informed consent
Study-specific consent
Initially, it would seem that the most straightforward
way of ensuring that the aims of informed consent are
met in biobank research is to implement best practice in
consent procedures, of the kind found in traditional hu-
man subject research. This would mean that informed
consent is obtained before the commencement of each
new study, and that the consent is specific to the risks
and benefits of the study being proposed. Thus, in this
model, samples contained in the biobank may only be
re-used in new studies after consent has been obtained
for that particular use either by the participant or, in
cases where that is not possible because the participant
has for one reason or another lost decision-making cap-
acity, an appropriate surrogate. This would allow poten-
tial participants (or their surrogates) to evaluate whether
they wish to participate with reference to specific infor-
mation and ensure that any agreement to participate re-
spects the autonomy of the participants to the greatest
extent possible.
However, implementing study-specific consent in bio-
banks is problematic. The structures and processes in-
volved in biobank research are vastly different from
those in clinical research. Consequently, the types of
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participation and interaction study-specific informed con-
sent was designed to address are not always present in the
biobank case [14]. There are three general differences be-
tween traditional human subject research and biobank re-
search: First, samples and data stored in biobanks will
potentially be used in new research projects dozens, or
hundreds, of times a year. Second, biobanks often store
samples and information over long periods of time (years
or decades). Third, where biobank research is concerned,
participants are recruited and samples are gathered before
most of the future research has been planned or even
thought of. While these structural changes have enabled
new kinds of research to be carried out – as seen, for ex-
ample, in Surén et al.’s study of the relationship between
the use of folic acid supplements during pregnancy and
autism spectrum disorders in children [15] – they also
challenge the traditional, study-specific model of informed
consent. The study-specific consent model requires re-
searchers to obtain consent to use already collected sam-
ples whenever a new study is begun. However, much of
the benefit of biobank research depends on researchers’
ability to reuse samples in many future studies. With this
in mind, it can readily be seen that the study-specific con-
sent model is liable to limit the utility of biobank research
in general (assuming that another consent model involv-
ing less frequent consent is ethically feasible) both be-
cause it requires resources that could have been used
for research to be devoted instead to the acquisition
of later consents and, not least, because failure to re-
ceive new consent from part of the study population
may give rise to various biases. Moreover, there is a
risk that repeated requests for consent will lead either
to consent fatigue, or to routinization, resulting in
turn either in fewer participants, or in watered-down
consent [8, 16].
Broad consent
Confronted with the challenges facing the study-specific
consent model, many biobanks have opted for a broad
consent approach [17]. Broad consent, as understood
here, is consent obtained at the time of enrolment in the
biobank against a background of assurances about the
overall scope and aims of the biobank as well as its gov-
ernance [18, 19]. Subsequently, samples and information
can be reused without obtaining a new consent, as long
as the use falls within the scope of the original broad
consent and also fulfills other regulatory requirements
such as approval from an ethics committee.
Having been informed about the general scope of the
biobank, participants are able to evaluate whether they
wish to consent to the overall biobank policy – and, by
extension, to the types of research that the biobank per-
mits upon any samples and information the participant
has provided. However, critics [6, 7, 20] have argued that
this model does not afford the same level of protection
as study-specific consent, and that it is simply a prag-
matic way to allow research to progress without inform-
ing participants about the specific risks and benefits of
future studies that have not yet been planned or even
conceived. Furthermore, in biobank research incidental
findings may be made, or intended research results may
lead to information, which could be relevant to the health
of a unique participant. Within a broad consent model, it
will generally be difficult, if not impossible, for researchers
to foresee these situations. This means that it will not be
possible to allow participants to make specific decisions
about the return of their individual research results when
they sign the consent form – something that is possible,
of course, in the study-specific consent model.
Dynamic consent
Problems like those described above have led several au-
thors to suggest new or adapted models of consent that
are specifically designed to meet the challenges of bio-
bank research. One of these is the dynamic consent
model. This seeks to harness the potential of modern IT
and communication systems to develop better proce-
dures for obtaining informed consent to biobank re-
search. The idea is to develop a digital platform which
allows participants to access and modify their consent
preferences continuously (including withdrawing con-
sent), as well as track, and follow up on, the activities of
the biobank [20].
The dynamic model offers a less cumbersome way to
obtain study-specific consents, since the digital interface
ensures that face-to-face contact is not necessary for
each renewal of consent. With this advantage, it may be
viable to enact study-specific consent procedures for
each study that a participant’s information or samples
are used in, even when the samples are being used in
new projects several times a year. Kaye et al. [7] have ar-
gued that alternatively the platform could be set up to
allow participants to choose to provide broad consent if
they wish to do so.
The challenges facing the dynamic consent will be dis-
cussed in greater detail later in the paper (see Section 4.2).
For now, we note merely that it is unclear whether this
model is capable of securing the enhanced levels of auton-
omy obtained in the study-specific consent model without
also encountering some of the issues the latter faces.
Other models
A fourth model of informed consent is “tiered consent”
[3, 21]. Tiered consent procedures allow potential partic-
ipants to at least partly tailor their consent preferences
around general categories. The model retains the under-
lying structure of the broad consent approach, in the
sense that, in it, consent is provided for future research
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in general rather than specific research projects. How-
ever, the participant is able to be more specific about the
uses that she is consenting to. Wolf and Lo found that
the specific tiers offered by Institutional Review Boards
(IRB) vary widely [21], but typically tiered consent pro-
cedures cover specific diseases or categories of diseases
(e.g. cancer research), public/private research, identified/
anonymous use, defined areas of research, or certain re-
search institutions or specific researchers [3]. The tiered
consent model is meant to allow participants to retain a
greater degree of control over the use of their samples
and data. It is also meant to be free of the problems as-
sociated with study-specific consent described above.
The meta-consent model shares many features of the
tiered consent [8]. The key difference is that, while the lat-
ter only allows the participant to provide general consent to
elected tiers of research, the meta-consent process is more
flexible in that it allows participants to associate different
kinds of consent with different tiers. For example, a re-
search subject might decide that she wants to give study-
specific consent to all future research that falls within the
tier of “dual-use” (i.e. research with additional military
applications), but that she is also happy to provide a single
broad consent to all future publicly funded public health
research. Meta-consent does not only allow participants to
provide consent preferences regarding different categories
of research, however. It also enables them to tailor their
consent preferences to specific categories of data – as they
may wish to do, for example, if they have special concerns
about genomic data. Participants can therefore design con-
sent portfolios which require them to make specific deci-
sions only about certain types of research.
While both the tiered and meta-consent models are
promising, in that they allow fine-grained participant
control without requiring consent for every study, they
face two obvious challenges. The first is that their effect-
iveness relies on the competence of the participants, and
specifically their ability to understand the possibilities,
and to construct a consent portfolio that is acceptable to
them. To be specific, while all consent models must
address differences in competency insofar as this affects
potential participants’ ability to provide informed consent,
the tiered and meta-consent models are doubly vulner-
able to this issue. This is because participants’ compe-
tency will not only affect their ability to provide
consent, but also the quality of the consent procedure
itself. The second is that tiered or meta-consent will
often require projects to be categorized in a way that is
not practicable. The main issue here, which will be dis-
cussed in more detail in Section 4.3, is that research
only rarely falls into neat categories of e.g. private/pub-
lic or national/international, which would allow the
type of categorization that is necessary to allow fine-
grained participant control.
Comparing the models
The models of informed consent presented above all
appear to solve some of the issues that have been identi-
fied within the broad and study-specific approaches to
informed consent, but we have also explained that,
prima facie at least, each contains challenges. From our
perspective, this is because they seem to be attempts to
treat the symptoms of a disease that has not yet been di-
agnosed. Without this diagnosis, it is difficult to say
whether the adapted models can successfully solve the
problems posed by the consent process in biobanks.
To provide the necessary diagnosis, and assess the ad-
equacy of the models, we will need to be clear about the
purpose of informed consent to participation in research
projects. This purpose is captured in two main aims. In-
formed consent aims to:
 Inform potential research subjects about the
relevant risks and benefits of participation, and the
goal of the research;
 Allow potential participants to exercise their
autonomy by accepting or refusing to participate
These aims should be interpreted broadly and include
information about direct health risks as well as informa-
tion about data storage and access policies affecting infor-
mational risks, and the intended goal of the research
including financial and commercial interests. The aims
have been central to the development of informed consent
in the research context and are contained (by implication
at least) within the major guidelines on informed consent
for human subject research around the world [13, 14, 22].
However, it remains an open question how the aims can
be met in biobank research. To answer this question, it is
necessary to provide a clearer picture of the structures
and processes within biobank research which have impli-
cations for the ethical protection of participants.
Relevant criteria for informed consent to Biobank
research
Obviously, in providing the most accurate information to
potential research subjects, the person seeking consent
should focus on information about risks that are relevant
to the project in question. The consent process should not
address the risk of being hit by a bus going to the test cen-
ter, for instance, since that risk is not especially large; nor
is it particularly associated with the proposed research
(unless, of course, the test center is located in an area
prone to bus accidents). In general, the consent process
should focus on informing candidate subjects about po-
tential harms that are sufficiently severe and sufficiently
likely to be realized. This will give them the most accurate
understanding of the risk profile of the project they are
considering participating in.
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In the informed consent process followed in traditional
medical research, the scope of things to consider is mostly
fairly straightforward: The important issues under consid-
eration are typically the risk of one or more physical or
psychological harms as a result of a physical act or inter-
vention that is part of the research protocol [23]. For ex-
ample, a study examining the effect of regular treadmill
exercise on muscle mass and composition might identify
the relevant risks as the risk of injury caused by physical
exertion, the risk of pain or infection associated with po-
tential biopsies of muscle mass, and so on.
Informational risk
Biobanks will often hold information about individual
participants, including information from medical re-
cords, along with biological samples and/or genetic in-
formation, for long periods of time. This means that
informational risk – i.e. the risk of harm resulting from
the revelation of personal information, including genetic
information, through hacks, leaks, or unintentional dis-
tribution – can be of great importance to the individual
enrolled in the biobank.
Two general contributory factors are involved in this
risk: First, biobank research carries with it an incentive
to gather as much data as possible on participants be-
cause at the time of procurement there is often no set
use for the data. (This is especially true for non-specific
disease biobanks.) The basic idea behind biobanks incen-
tivizes broader, and more intensive data collection, and
the retention of all data, independently of the dataset’s
current usefulness. The effects of this incentive can be
seen in recent efforts to combine databases across bio-
banks in order to achieve even larger databases and
more ‘fine-grained’ data, and in the policy of some bio-
banks of continuing to gather and update information in
the biobank through links to electronic medical records
and the like for the duration of participation [12]. Sec-
ond, while stringent security protocols might be ob-
served, the simple fact that personal and potentially
sensitive information is gathered, stored within and
shared by the biobank for long periods of time will put
the information at risk.
But it is noticeable that their likelihood of being actu-
alized depends more on the governance, policies, and
competence of the biobank than it does on specifics of
the research being carried out. It remains the case that
participants will be put at risk if samples and data are
shared with researchers who have insufficient data and
sample security practices. However, the likelihood of
participants being put at risk in this way in large part
depends on the distribution policies of the biobank, and
the agreement it has in place with researchers obtaining
access to samples and data. Furthermore, risk also at-
taches to the storage and distribution policies of the
biobank as such, and the combination of data from
many sources significantly heightens them [24]. Study-
specific informed consent procedures are not equipped
to deal with such risks, since the risks cut across the
specific studies.
Potential for violations of participants’ values
Another novel issue that biobanking raises turns on the
potential transgression of participants’ values. Because
biobanks often provide samples and data to many differ-
ent research projects every year, a research project ap-
proved by broad consent might end up contradicting the
values of some contributors to the biobank. This issue is
especially likely to arise in biobanks where participation
stretches over long periods of time. First, the values of
the participant may shift over time, with the result that
the values that led her to provide consent are abandoned
or superseded by others. That may mean that research
that is initiated may violate the participant’s values at a
later time. Second, as research methods and aims de-
velop, new research projects may be proposed which
neither the participant nor the biobank administrator
envisaged at the time of enrolment, thereby making it
difficult, or impossible, to know whether a specific re-
search project is objectionable to some portion of the
cohort. Even broad guidelines given at the time of enrol-
ment may well not be sufficient to protect individuals
from this risk of violation of their values.
Criteria for informed consent in biobanks
In the literature there has been a tendency to judge con-
sent models applied to biobanks on their ability to afford
the same level of protection as traditional, study-specific
consent (for examples, see [2, 6, 20]). However, as we
have explained above, the types of protection needed in
biobank research differ markedly from the security trad-
itional consent models are designed to offer (which re-
lates chiefly to known, specific, and often physical risks
associated with a particular study). Thus, any fair assess-
ment of a consent model for biobank research must be
based on criteria that are relevant to this particular kind
of research, rather than on a comparison with existing
models. We propose three criteria that the consent
model should fulfill:
1. Information Criterion: Inform potential
participants about the relevant risks and benefits of
biobank research (especially informational risk) so
that she can make an autonomous choice about
participation in light of this information;
2. Value Criterion: Offer participants the opportunity
to assess whether the research to be conducted
with biobank materials is in line with their personal
values, and to make consent decisions based on this
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3. Duration Criterion: Afford ethical protection for
the duration of the subject’s participation in the
biobank, and give the subject a real and meaningful
opportunity to reassess her consent for that
duration and an actionable right of withdrawal
(provided, of course, that the participant is still alive
and competent).
The information and value criteria are a direct conse-
quence of the analysis of the relevant risks of participa-
tion in biobank research, as described above. Notably,
the information criterion is formulated as it is in light of
the fact that the risks involved in participation in bio-
bank research depend largely on features of the biobank
itself, rather than on the specifics of any given study.
The duration criterion is of special concern in biobank
research. While a right to withdraw has been standard in
informed consent procedures for many years, biobank
research requires more than just stating the availability
and terms of such withdrawal. Participation in biobanks
takes place over long periods of time, without the direct
participation of the individual. This means there is a
need to put in place ongoing ethical protection in order
to ensure participant autonomy, as there is a greater risk
that subjects will forget that they are participants, or
simply cease to think about their involvement [5]. This
problem is especially challenging for broad consent
models, because where they are applied there will nor-
mally be very limited, or no, continuing communication
with participants. Thus, it is more likely that participants
will be unaware of, or will have forgotten about, their
participation and their right to withdraw.
Fulfilment of the three criteria should ensure that an
informed consent model is successful in providing con-
sents satisfying the aims of informed consent and affords
adequate protection for participants. This means that
the models of informed consent that have been proposed
for adoption in biobanks can be evaluated against these
criteria in order to determine whether any of them pro-
vides superior protection for participants.
Evaluating proposed consent models against the
criteria
We will now test the main models of informed consent
against the criteria set out above.
Study-specific consent
Study-specific consent would require biobanks to obtain
consent for each study. Clearly this would have a substan-
tial impact on the ability of biobanks to carry out research,
and would place a particular burden on disease-specific bio-
banks that work with end-of-life patients or competence-
limiting diseases such as dementia. This issue has been
discussed in the literature previously, especially by
proponents of broad consent [4, 23], and dynamic
consent has been presented, in part, as a solution to
it [7]. As a consequence, the study-specific consent
model has generally not been adopted in biobanks.
Study-specific consent probably also fails to meet the
information criterion, as it is structured to focus on in-
formation about the risks of a particular study, while the
relevant risks in biobanks, as explained above, are a con-
sequence of general biobank governance, policy, and
competence. This means that a consent process with
focus on specific uses of samples is not geared to offer
participants relevant protection.
The maintenance of adequate study-specific consent
would also be likely to require such frequent efforts to
obtain separate consents that a balance would have to be
struck between the demands of consent and the re-
sources available to those charged with obtaining each
consent. The former may well have to be traded off
against the latter, with corners being cut. This could put
the quality of an individual’s consent at risk, especially
since there is some evidence that understanding is im-
proved by face-to-face contact in the consent process
[25, 26], which is a resource intensive process. In all likeli-
hood, then, the consent procedures for secondary research
on samples would end up being administered without
face-to-face contact. There is good reason to believe that
the quality of the consent would be poorer as a result.
Dynamic consent
If, as suggested by Kaye et al. [7], dynamic consent is
employed as a delivery system for study-specific consent,
it must initially be assumed that it will also suffer from
the problems besetting study-specific consent just dis-
cussed. However, this does not exclude the model from
consideration, since dynamic consent can be used to de-
liver many different forms of consent, as its proponents
have pointed out [7]. In theory, dynamic consent may, in
effect, ‘drift’ between consent models, and thereby in-
herit the benefits of each, depending on the context.
However, in practical terms, the dynamic consent plat-
form must deliver consents based on some procedure or
other, and that procedure should be based on a defined
and recognized method of consent (like the methods
described in the other consent models) in order for the
platform to function in an acceptable way. In this case, it
must be assumed that when the dynamic consent plat-
form is used to deliver study-specific consent, both the
benefits and costs of the study-specific consent model
apply. This will be the case unless there is some special
feature of the dynamic consent, or the use of a particular
consent model within this platform, that ensures that a
certain cost does not accrue in the case at issue.
Thus, if it is suggested – as it is, for example, in Kaye
et al.’s paper [7] – that dynamic consent has the
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advantage that it promotes autonomy as a consequence
of its ability to deliver study-specific consents, then it
must also be acknowledged that, prima facie at least, the
costs associated with the study-specific consent model
are nevertheless a drawback. While supporters of the dy-
namic approach can rightly claim that, with its mode of
delivery, it is capable of offsetting some of the inefficien-
cies of the more traditional study-specific consent model,
they must also accept that at least some of the challenges
posed by study-specific consent (of the kind touched upon
above) must also be addressed: This is inevitable, given
that the dynamic model must, in reality, commit to a par-
ticular consent model in order to function.
In addition, the model suffers from a unique weakness:
It runs the risk of failing to protect the autonomy of the
participants sufficiently, as dynamic consent is unable to
ensure that potential participants make decisions about
participation that are based on a high level of information
and understanding without external influence or coercion.
This issue is relevant to, and needs to be addressed in, all
of the consent models presented in this paper, but the dy-
namic consent procedure is particularly vulnerable to it
because it does not enable adequate protections to be put
in place. Dynamic consent intentionally differs from trad-
itional consent by allowing participants to provide consent
in uncontrolled conditions. Traditional consent proce-
dures emphasize the minimization of undue influence and
coercion by placing controls on the consent environment
(e.g. by ensuring that consent is provided in private, with-
out time pressure, and with the oversight of a professional
who can assess the competency and mental state of the
participant to an extent). In practice the digitally adminis-
tered consent procedure might be able to screen for
people with mental disabilities or other impairments that
are registered in public health records, but it cannot en-
sure to a reasonable degree that potential participants are
not subjected to undue influence. In the simplest terms,
this might mean that a potential participant is in an envir-
onment – e.g. in the presence of a friend or family mem-
ber who holds certain values dear or has an interest in the
person making a particular decision about specific areas of
research – where she feels pressured to make decisions
she would not otherwise have made.
Tiered/Meta-consent
The tiered and meta-consent models provide categories
of context, research methods and aims, and types of data
which allow participants to be aware of the specific tiers
on which their samples and data can be used, and to
withhold consent from uses that are not in line with
their values, while continuing to participate in the bio-
bank. However, these models rely on the ability of those
running the biobank to draw relatively clear definitional
boundaries around the different categories. It is not clear
that this aim is as easily achieved in practice as it is in
theory, especially as new research areas and methods
emerge over time.
Ploug and Holm [8], who advocate the meta-consent
model, suggest ‘private’ and ‘public’ as potential tiers
that can be used to differentiate between consent stan-
dards. However, today much (if not most) of the medical
research being pursued in public institutions is conducted
in partnerships with private stakeholders. The partner-
ships range from simple knowledge-sharing, or consulting,
all the way to fully integrated collaborations involving
shared patent rights. In other words, modern research
does not offer a simple dichotomy between public and pri-
vate research, or for-profit and not-for-profit research,
and to offer such a choice between these categories would
be inefficient at best and misleading at worst.
Given this, biobanks will be obliged either to deny
sample use in all borderline cases (which would hamper
research progress) or to make judgments internally with-
out the input of the participant who provided the con-
sent (which would water-down the consent). Thus, on
closer inspection meta-consent seems to not have the
fundamental advantage over broad consent claimed for
it: It does not, in other words, offer the participant a
greater degree of control. It seems that the tiered and
meta-consent models aim to give participants a more
well-defined and finely tuned web of categorization than
is practically possible. In this way, the models fail the
duration criterion, as developments in the methods and
aims of research will diminish the level of protection
provided by earlier consents over time.
Even if a solution to this problem of emerging, or sim-
ply changing, research focus is found, the practical im-
plementation of the models is bound to leave a lot to be
desired. The hope that a tiered or meta-consent model
would allow participants to exert greater control over
the way their samples and data are used without resort
to a study-specific consent model (along with its associ-
ated issues) is unlikely to be fulfilled. The model requires
repeated re-categorizations of research and associated
re-consent procedures, and this points to a larger under-
lying nexus of issues. The tiers involved in the models
do not by themselves represent values, but rather cat-
egories of research. This creates several problems. First,
potential participants will make decisions about the cat-
egories they wish to consent to (or, in the case of meta-
consent, about which model of consent they would like
to be applied to a specific category). Their decisions will
be based on their underlying values, together with their
beliefs about the category, or categories, in question.
However, these values are not explicitly recorded against
the categories. As a consequence, it will not be possible
for the biobank administrator, or user, to know what
value judgments led a person to provide consent for a
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specific category. By extension, administrators and users
will be in no position to assess what changes to the
boundaries of the category can be made without step-
ping beyond the expectations under which the partici-
pant’s consent was originally given.
Imagine a participant has provided consent for her
samples and data to be used in cancer research. She has
done so because she believes that cancer research is
valuable, but also because she assumes that this type of
research will not involve the cloning of human tissue – a
restriction which, for her, is a condition of consent. If at
a later time human tissue cloning becomes an important
technique in a certain type of cancer research, the bio-
bank administrators will be likely to make her samples
available for this kind of research, because they have no
record of the underlying values and information that led
the participant to give her consent originally. Unwit-
tingly, the biobank would involve the participant in re-
search that is contrary to her values. In this way, the
tiered or meta-consent models may fail the value criter-
ion, because the boundaries of specific categories will
generally be based on a highly uncertain interpretation
of the likely values and beliefs that would guide partici-
pants’ decisions about those categories.
Lastly, it should be pointed out that attempts to devise a
set system of categorization is bound to reflect a set of
values – values which define the categories of relevance,
their boundaries, the tiers, and so on. This raises a con-
cern about the fairness of tiered and meta-consent, since
potentially it means that minority groups with alternative
value sets may not enjoy the same level of control and
protection from these models as the majority group would
(see [5] for some empirical work on the way demographic
and other factors affect people’s perceptions of biobank
research, and their willingness to participate).
Broad consent
Having identified a number of problems with the study-
specific and adapted models, we turn now to consider
broad consent. This model has been criticized for not
living up to the standards of informed consent [6]. The
complaint is that it fails to provide potential participants
with enough information, or information of sufficient
depth, about the specific research projects for which
they will provide samples or data. If this were correct, it
might be concluded that the model fails the information
criterion. However, in light of the capacity of broad
consent to identify the relevant risks of participation in
biobank research, it can be argued that this model is
actually particularly well-placed to meet this criterion, as
the main risk of participation in biobank research is in-
formational risk.
Importantly, this risk is mainly a consequence of
having potentially sensitive personal information placed
in the biobank and stored there for long periods of time.
Further, the likelihood of the risk being actualized is
mostly a consequence of the governance, competence,
and policies of the biobank [10]. Consequently, it is en-
tirely possible for the broad consent process to cover
relevant information about the informational risks of
participating in the biobank, and to describe the struc-
ture and governance of the biobank at the time of
sample collection, and thus inform candidates about the
relevant risks of participation.
By extension, broad consent is also effective in sup-
porting the potential participant’s autonomy. The struc-
ture of the consent sought here encourages participants
to reflect on the general risks of informational harm that
the biobank creates as a whole, rather than on the spe-
cific risks associated with any given research project.
Additionally, when consent is structured as a single con-
sent, biobanks can provide a much deeper consent
process by investing more resources in the practical
process of consent at the time of enrolment, which facil-
itates greater investment in face-to-face time for partici-
pants. This lowers the risk of uninformed decision-
making and undue external coercion that features in
some other models of consent. Moreover, the broad
consent model has a less severe impact upon the ability
of scientists to carry out research within the biobank.
Overall, then, broad consent appears to successfully sup-
port both the information criterion and participant au-
tonomy while promoting the efficient use of resources.
Drawbacks of broad consent
However, this leaves the value criterion and the duration
criterion. By providing broad consent at the outset, par-
ticipants will gain some protection against their samples
being used in research that is contrary to their values,
but that protection is rather shallow, since the broad scope
of the consent will probably not include enough detail to
ensure that all proposed research projects clearly fall on
one side of a boundary or the other. It is also a concern
that, as research aims and methods evolve over time, it is
unlikely that the parameters of the broad consent obtained
will readily apply to all of those aims and methods. There
is a real risk that some participants will end up participat-
ing in research that they would not have agreed to, if they
had been asked for a study-specific consent.
Broad consent may also reinforce the idea that ‘ethical
work’ is concluded when the consent has been obtained.
This is of course a general misconception, not one that
the broad consent model uniquely invites, and therefore
it should not be seen as an argument against the model.
However, it might be said that even if the broad consent
model is not unique in being exposed to this misconcep-
tion, it might be more likely to occur when this model is
used. It might be added that, all else being equal, a
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model which makes this mistake less likely (e.g. a study-
specific consent model) is superior in this regard.
If participants are to receive relevant protection over
the duration of their participation, their values must
continue to be considered throughout the life of the bio-
bank. If participants provide a broad consent at the time
of enrolment but are not aware of future developments
in the work of the biobank, they are unlikely to be fully
aware of the scope of research they are enrolled in,
which means that the value of their right to withdraw is
questionable. To be ethically acceptable, then, the broad
consent model needs to be deepened.
A proposal for a broad consent model that is also
deep
Broad consent as it stands does not provide adequate
protection. It fails to satisfy both the value criterion and
the duration criterion. However, we believe that these
challenges can be addressed and to some extent met. In
essence, we propose that two elements are needed in
order to ensure that the broad consent provides the re-
quired level of ethical protection for participants: A
strong and continuous ethical review process, with the
specific mandates for proposed research resting on eval-
uations of whether that research falls within the scope of
the broad consent, and continuous provision of informa-
tion to participants.
Ethical review
An ethical review must be mandated and guaranteed if
broad consent is to serve its purpose. Earlier broad con-
sent proposals have relied largely on existing ethics re-
views to provide the ethical assessment of particular
studies, given the broad consent provided by partici-
pants. However, as participants are not able to assess
each new study in accordance with their values, an add-
itional step in the review is necessary. Independently of
other ethical review questions, a study intending to use
data from the biobank should be assessed by the biobank
administrators (or in relevant cases by national/regional
ethics boards) to determine whether it falls within, and
complies with, the boundaries of the broad consent that
participants have provided. Whether this can be done
within existing structures will depend on the setup of
the biobank and the context in which it operates, but it
should be explicitly stated that this step of the review is
both mandatory and independent of other ethical and
practical considerations when studies are being ap-
proved. Thus, the following requirement is essential for
the ethical approval of a new study undertaken under an
existing broad consent: It must have been found to be
within the scope of the broad consent as judged by the
relevant kind of ethical review.
It will be necessary for the biobank to clearly set out the
conditions which qualify a study for this extra level of eth-
ical scrutiny, although these conditions will depend on
both the features of the biobank and the population it
contains. In setting out these conditions, the biobank must
be mindful of potential minority views or values which
might be violated, even if the study remains uncontrover-
sial for the majority of participants. The review needs to
have the sole aim of establishing whether the proposed re-
search falls within the scope of the broad consent that has
been obtained from participants. In this way, the review
will ensure that participants’ values are considered in
every decision without the need to re-contact them.
For this process to be effective, the original broad con-
sent must involve clarity about the scope of the biobank.
This requires the broad consent to identify the core
values that will guide decision-making about future re-
search projects as well as any potential research areas
that are excluded from the scope. The increased level of
specificity within the scope of the broad consent, which
is necessary to ensure the proper functioning of the eth-
ical review, will create a certain degree of inflexibility in
terms of what types of research can be undertaken using
the information and samples held by the biobank. Unfor-
tunately, this requirement will create both intended and
unintended restrictions on future research projects which
could have been approved under a study-specific consent
approach, and it is to be expected that with developments
in research aims and methods this issue may be exacer-
bated over time. However, without this clearly defined
scope, the protections provided by the ethical review are
fundamentally undermined, and for this reason this is a
necessary concession within the broad consent model.
It must be emphasized that evaluations will be made
without considering the opinions of each participant, cre-
ating some level of risk that a participant would disagree
with an evaluation, especially in borderline cases, and thus
the possibility of participants being unwittingly enrolled in
research that is contrary to their values. While this is an
undesirable consequence of the model, it should be clear
from the above that no model except the study-specific
consent model can provide a higher degree of protection
from this risk. Since study-specific consent suffers from
several other issues that make it an unattractive candidate
for implementation, and since broad consent remains at
least on par with all other models on this issue, the latter
could be regarded as the least problematic alternative. It is
also worth noting that this issue can be further addressed
(although not completely resolved) through the imple-
mentation of continuous information for participants.
Continuous information
By continuous information we mean regular communi-
cation with all participants in the biobank who are still
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alive and competent describing the work that has been
done within the biobank since the last communication
and giving information about future plans to the extent
that this is possible. This must include information
about notable results from recent studies as well as
newly approved research. It might also contain more
general information about developments within the field
of the biobank, and about how these relate to the oper-
ation of the biobank. This information should be pro-
vided at defined, regular intervals (e.g. once a year).
While many biobanks provide information of this or a
similar sort of their own accord, we propose that the
provision of continuous information should be man-
dated within the broad model of informed consent sug-
gested here. It would no longer simply represent best
practice. Instead it would become a necessary condition
of compliance with the consent given. Specifically, it
would be stipulated in the consent form that potential
participants are asked to sign that the validity of any
consents they provide is contingent upon the biobank
providing continuous information meeting the standards
described here (taking into consideration the context of
the particular biobank and the implementation of the
model of consent suggested here).
Providing this type of information has many benefits.
First, it allows the biobank to build trust with participants.
There is evidence that such trust is central to willingness
to participate [27]. Second, continuous information allows
participants to keep abreast of the evaluations made in the
ethical review process. This ensures that they are aware of
the research that is taking place and allows them to evalu-
ate whether their values continue to align with the wider
activities of the biobank and consider whether they still
wish to be enrolled. This, in combination with the con-
tinuous review process, offers a further safeguard which
reduces the possibility of participants being enrolled in
research that is contrary to their values and thus meets
the value criterion.
Third, continuous information ensures that surviv-
ing participants who are still competent are always
aware of their participation and their right to with-
draw. In this way, such information also serves to en-
sure that participants have a meaningful right of
withdrawal at any time – which is a central concern
of biobank research, as argued above – thereby satis-
fying the duration criterion. Thus, by thinking about
the broad consent model in a wider perspective, and
by being clear about the necessary criteria that in-
formed consent must fulfil in the biobank context, it
is possible to ensure a very high degree of fulfilment
of all three of the criteria we have set out. This is
important since, as far as we have been able to deter-
mine, the current, narrower descriptions of broad
consent neglect the value and duration criteria.
The provision for continuous information is an im-
portant element in ensuring that broad consent satisfies
the criteria set out earlier in the paper. Could it, how-
ever, lead to problems similar to consent fatigue? That
is, would participants who are regularly presented with
information in an intrusive and uninvited manner de-
velop “information fatigue”, and would this lead them
eventually to opt out of the biobank? It cannot be denied
that this problem may affect enrolment in the biobank,
but two important points should be considered before
we throw the baby out with the bathwater. First, while it
may be possible to address the problem by providing in-
formation only when relevant changes are made, or only
when information matches the participant’s preferences,
there is a worry that the strategy would raise its own is-
sues. Thus, if participants prefer minimal information,
communication could become so infrequent that the in-
formation provided then fails to satisfy its purpose in
terms of ensuring awareness of participation. Also, any
attempt to demarcate when “relevant”, or “important”,
changes have taken place would have to rely on general as-
sumptions about participants’ preferences and motivations
that would fail to ensure equal protection for all partici-
pants. Second, it is arguable that any risk of information
fatigue of the kind we are envisaging is unlikely to be as
serious as the risks associated with consent fatigue. Con-
tinuous information allows participants to be as involved
in the biobank as they wish. While it offers information to
participants that are concerned about, or interested in, the
work of the biobank, it does not actually require the par-
ticipant to engage with the information. If a participant is
content to participate without reviewing the information,
this is a genuine option. By contrast, repeated study-
specific consent requests do require participants to engage
with the biobank, and to make decisions on a regular basis,
irrespective of their wishes.
Conclusion
The implementation of satisfactory informed consent
processes in biobank research has proven difficult for
both practical and ethical reasons. The structure of biobank
research has forced a rethink of study-specific consent, and
newly proposed, alternative models have been challenged
on the sufficiency of their protections. In this article we
have examined the most frequently proposed models and
noted their major alleged weaknesses. Following this, by in-
vestigating the basic aims of informed consent as well as
the unique challenges that are presented by the structure of
biobank research, we have formulated a set of criteria for
informed consent in biobanks against which the various
biobank consent models can be evaluated.
The criteria reflect the fact that the risks traditionally
considered most important in discussions of informed
consent – namely, those of direct physical damage – are
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less important in the context of biobank research: Here,
risks of informational harm and the violation of partici-
pants’ values matter most. The criteria for informed con-
sent in biobanks suggested in this paper are therefore
based on the idea of managing these potential risks.
Given the criteria, and their focus on the unique risk
profile of biobank research, we find that broad consent
achieves the underlying aims of the informed consent
process better than any other evaluated model. It is able
to provide information about the relevant risks of par-
ticipation, as these are, to a large extent, a consequence
of more general facts about the biobank and its scope
rather than any given research project. Broad consent
is also effective in ensuring participant autonomy: Its
structure encourages participants to focus on relevant
information, and since consent is only gathered at the
time of enrolment, biobanks are able to expend the
necessary resources on creating an environment and
information exchange that encourages autonomous
decision-making.
We have argued that the broad consent model can
only be an adequate model of consent if it is also deep.
We have claimed, however, that the necessary depth can
be added by thinking about the consent process in a
wider perspective, ensuring that any consents obtained
are based on sufficient information that is given to par-
ticipants over time, and putting in place an effective
right of withdrawal facilitated by that continuous in-
formation provision.
Broad consent is not a perfect solution to the prob-
lem of informed consent in biobanks. Even with the
deep nature of the modified broad consent process
set out here, there is still a risk that participants’
values will be inadvertently violated by future re-
search. Furthermore, the necessary ethical review
process requires the scope of the biobank to be de-
fined fairly rigidly, and it is a foreseeable consequence
of this that some future research that would have
been allowed under alternative consent models might
not be possible under the model we have proposed.
However, while both of these drawbacks are undeni-
able, in our view the broad and deep model we have
set out is a better model of consent for biobanks than
any of its competitors. It is best suited to deliver par-
ticipant protection while achieving the research aims
of the biobank.
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